Alexion AstraZeneca Rare Disease has completed its acquisition of LogicBio Therapeutics, Inc., a pioneering genomic medicine company, for $2.07 per share.   The acquisition creates an opportunity to accelerate Alexion’s growth in genomic medicines through unique technology, an experienced rare disease R&D team, and expertise in preclinical development. Frederic Chereau, CEO of LogicBio, will join Alexion as Senior Vice President, Strategy and Business Development.   LogicBio becomes a wh...